Skye Bioscience (SKYE) Long-Term Debt Issuances (2013 - 2026)
Skye Bioscience (SKYE) posted quarterly Long-Term Debt Issuances of $71525.0 for Q1 2026, up 101.52% quarter-over-quarter from -$4.7 million in Q4 2023.
Skye Bioscience (SKYE) Long-Term Debt Issuances (2013 - 2026) Analysis & Trends
Skye Bioscience (SKYE) has reported Long-Term Debt Issuances for 6 consecutive years, with $71525.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Long-Term Debt Issuances changed N/A year-over-year to $71525.0; the TTM figure through Mar 2026 stood at -$4.6 million (up 1.52% YoY), while the FY2023 annual figure was $259335.0, down 5.88% from the prior year.
- Long-Term Debt Issuances rose to $71525.0 in Q1 2026 per SKYE's latest filing, from -$4.7 million in the prior quarter.
- Across five years, Long-Term Debt Issuances topped out at $71525.0 in Q1 2026 and bottomed at -$4.7 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Skye Bioscience | 10.86 Mn | 10.86 Mn | - | 107,288.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 71,525.00 |
| Mar 31, 2026 | 71,525.00 |
| Dec 31, 2023 | -4.71 Mn |
| Dec 31, 2023 | -4.71 Mn |
| Sep 30, 2020 | 333,300.00 |
| Sep 30, 2020 | 333,300.00 |
| Mar 31, 2018 | 400,000.00 |
| Mar 31, 2018 | 400,000.00 |
| Apr 30, 2014 | 11,883.00 |
| Apr 30, 2014 | 11,883.00 |
| Oct 31, 2013 | 26,661.00 |
| Oct 31, 2013 | 26,661.00 |
| Jul 31, 2013 | -26,661.00 |
| Jul 31, 2013 | -26,661.00 |
| Jan 31, 2013 | 32,000.00 |
| Jan 31, 2013 | 32,000.00 |